• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by DENTSPLY SIRONA Inc.

    7/1/25 4:21:57 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care
    Get the next $XRAY alert in real time by email
    S-8 1 ds-formsx806262025.htm S-8 Document

    As filed with the Securities and Exchange Commission on July 1, 2025
    Registration No. 333-
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933


    DENTSPLY SIRONA Inc.
    (Exact name of registrant as specified in its charter)
    Delaware
    (State or other jurisdiction of
    incorporation or organization)
    39-1434669
    (I.R.S. Employer
    Identification No.)

    13320 Ballantyne Corporate Place
    Charlotte, North Carolina 28277-3607
    (Address of principal executive offices)

    DENTSPLY SIRONA Inc. 2024 Omnibus Incentive Plan (as amended on May 21, 2025)
    (Full title of the plan)

    Richard C. Rosenzweig
    Executive Vice President, Corporate Development, General Counsel and Secretary
    DENTSPLY SIRONA Inc.
    13320 Ballantyne Corporate Place
    Charlotte, North Carolina 28277-3607
    (844) 848 - 0137
    (Name, address and telephone number,
    including area code, of agent for service)

    With copies to:
    Lillian Tsu & Julia L. Petty
    Cleary Gottlieb Steen & Hamilton LLP
    One Liberty Plaza
    New York, New York 10006

    ________________________
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non‑accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b‑2 of the Exchange Act.
    Large accelerated filer    ☒    Accelerated filer    ☐
    Non‑accelerated filer    ☐  (Do not check if a smaller reporting company)    Smaller reporting company    ☐
    Emerging growth company    ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐




    EXPLANATORY NOTE
    Pursuant to General Instruction E of Form S-8, DENTSPLY SIRONA Inc. (the “Registrant”) is filing this registration statement on Form S-8 (this “Registration Statement”) with the U.S. Securities and Exchange Commission (the “Commission”) to register, in connection with the Registrant’s 2024 Omnibus Incentive Plan (as amended on May 21, 2025), an additional 11,260,000 shares of the same class as registered under the Registrant’s effective registration statement on Form S-8, File No. 333-279714, filed with the Commission on May 24, 2024 (the “Earlier Registration Statement”). The contents of the Earlier Registration Statement, where applicable, are hereby incorporated by reference, except that the provisions contained in Part II of such Earlier Registration Statement are modified as set forth in this Registration Statement.

    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
    Item 3.Incorporation of Documents by Reference.
    The following documents, as filed by the Registrant with the Commission pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated by reference in this Registration Statement:
    (1)The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on February 27, 2025;
    (2)The Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2025 filed with the Commission on May 8, 2025;
    (3)The Registrant’s Current Reports on Form 8-K filed with the Commission on February 6, 2025 (excluding Item 7.01 and Exhibit 99.1), March 19, 2025, May 8, 2025 (excluding Item 2.02 and Exhibit 99.1), May 22, 2025, May 29, 2025 (excluding Item 7.01, Exhibit 10.1, and Exhibit 99.1), June 4, 2025, June 6, 2025, and June 12, 2025; and
    (4)The description of the Registrant’s Common Stock, par value $0.01 per share, contained in Exhibit 4.4 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the Commission on March 2, 2020, including any amendment or report filed for the purpose of updating such description.
    In addition, all reports and other documents filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post‑effective amendment to this Registration Statement that indicates that all securities offered hereunder have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any document or any statement contained in this Registration Statement, in an amendment hereto or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.







    Item 8.    Exhibits.
    Exhibit
    Number
    Description
    4.1
    Second Amended and Restated Certificate of Incorporation of DENTSPLY International Inc. (incorporated by reference to Exhibit 3.1 to Registrant’s Annual Report on Form 10-K for the year ended December 31, 2016, filed with the Commission on March 1, 2017)
    4.2
    Certificate of Amendment to Second Amended and Restated Certificate of Incorporation of DENTSPLY SIRONA Inc. (incorporated by reference to Exhibit 3.1 to Registrant’s Current Report on Form 8-K filed with the Commission on May 23, 2018)
    4.3
    Seventh Amended and Restated By-Laws of DENTSPLY SIRONA Inc. (incorporated by reference to Exhibit 3.1 to Registrant’s Current Report on Form 8-K filed with the Commission on August 2, 2023)
    4.4
    DENTSPLY SIRONA Inc. 2024 Omnibus Incentive Plan (incorporated by reference to Exhibit 4.4 to the Registrant’s Registration Statement on Form S-8 filed with the Commission on May 24, 2024)
    4.5
    Amendment No. 1 to the DENTSPLY SIRONA Inc. 2024 Omnibus Incentive Plan (incorporated by reference to Appendix A of the Registrant’s 2025 Proxy Statement filed with the Commission on April 9, 2025)
    5.1
    Opinion of Cleary Gottlieb Steen & Hamilton LLP
    23.1
    Consent of Cleary Gottlieb Steen & Hamilton LLP (included in Exhibit 5.1)
    23.2
    Consent of Independent Registered Public Accounting Firm - Deloitte & Touche LLP
    23.3
    Consent of Independent Registered Public Accounting Firm - PricewaterhouseCoopers LLP
    24.1
    Power of Attorney (contained on signature page hereto)
    107
    Filing Fee Table




    SIGNATURES
    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S‑8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Charlotte, North Carolina on the 1st day of July, 2025.
    DENTSPLY SIRONA INC.
    Date: July 1, 2025By:/s/ Simon D. Campion
    Simon D. Campion
    President and Chief Executive Officer
    POWER OF ATTORNEY

    Each person whose signature appears below appoints Simon D. Campion and Richard C. Rosenzweig, each of whom may act without joinder of the other, the individual’s true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for the person and in his or her name, place and stead, in any and all capacities, to sign this Registration Statement and any or all amendments (including post-effective amendments) to this Registration Statement and any registration statement for the same offering, filed pursuant to Rule 462 under the Securities Act, and to file the same with all exhibits thereto and all documents in connection therewith with the Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully and for all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or their substitutes may lawfully do or cause to be done by virtue hereof.




    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.

    NameTitleDate
    /s/ Simon D. CampionPresident and Chief Executive Officer and DirectorJuly 1, 2025
    Simon D. Campion(Principal Executive Officer)
    /s/ Matthew E. Garth
    Executive Vice President and Chief Financial Officer July 1, 2025
    Matthew E. Garth(Principal Financial Officer)
    /s/ Kevin J. Czerney
    Chief Accounting OfficerJuly 1, 2025
    Kevin J. Czerney(Principal Accounting Officer)
    /s/ Gregory T. Lucier
    Chairman of the Board of DirectorsJuly 1, 2025
    Gregory T. Lucier
    /s/ Michael J. BarberDirectorJuly 1, 2025
    Michael J. Barber
    /s/ Willie A. DeeseDirectorJuly 1, 2025
    Willie A. Deese
    /s/ Brian T. GladdenDirectorJuly 1, 2025
    Brian T. Gladden
    /s/ Betsy D. HoldenDirectorJuly 1, 2025
    Betsy D. Holden
    /s/ Clyde R. HoseinDirectorJuly 1, 2025
    Clyde R. Hosein
    /s/ Jonathan J. MazelskyDirectorJuly 1, 2025
    Jonathan J. Mazelsky
    /s/ Daniel T. ScavillaDirectorJuly 1, 2025
    Daniel T. Scavilla
    /s/ Leslie F. VaronDirectorJuly 1, 2025
    Leslie F. Varon
    /s/ Janet S. VergisDirectorJuly 1, 2025
    Janet S. Vergis


    Get the next $XRAY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $XRAY

    DatePrice TargetRatingAnalyst
    4/15/2025$14.00Overweight → Equal-Weight
    Morgan Stanley
    3/13/2025Buy → Hold
    Needham
    2/14/2025$20.00Equal Weight
    Wells Fargo
    1/23/2025$30.00 → $20.00Buy → Hold
    Jefferies
    1/7/2025$20.00Outperform → In-line
    Evercore ISI
    12/4/2024$21.00Neutral
    Mizuho
    11/7/2024Outperform → Market Perform
    Leerink Partners
    10/25/2024$34.00 → $29.00Buy
    Needham
    More analyst ratings

    $XRAY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Dentsply Sirona Prices Offering of $550 million of Junior Subordinated Notes

      CHARLOTTE, N.C., June 05, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced it has priced an offering (the "Offering") of $550 million aggregate principal amount of its 8.375% Junior Subordinated Notes due 2055 (the "notes"). The Offering is expected to close on June 12, 2025, subject to customary closing conditions. The notes will bear interest at a fixed rate of 8.375% per year until September 12, 2030 (the "First Reset Date"). On and after the First Reset Date, the interest rate per year on the notes for each reset period will be equal to the five-year U.S. Treasury rate as of the most recent reset interest rate determinati

      6/5/25 5:35:00 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • Dentsply Sirona Appoints Matthew E. Garth as Chief Financial Officer

      CHARLOTTE, N.C., May 29, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Matthew E. Garth has been appointed Executive Vice President and Chief Financial Officer, effective May 30, 2025. Mr. Garth brings nearly 30 years of proven financial management expertise to Dentsply Sirona, with a focus on driving value creation. He most recently served as Chief Financial Officer & Chief Administrative Officer of The Scotts Miracle-Gro Company, a global leader of branded consumer lawn and garden products. Prior to ScottsMiracle-Gro, Mr. Garth held numerous financial leadership roles at large, multinational companies, including Min

      5/29/25 4:30:00 PM ET
      $MTX
      $SMG
      $XRAY
      Major Chemicals
      Industrials
      Agricultural Chemicals
      Medical/Dental Instruments
    • Dentsply Sirona Declares Quarterly Cash Dividend

      CHARLOTTE, N.C., May 27, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) announced that its Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, an indicated annual rate of $0.64 per share. The dividend is payable on July 11, 2025, to holders of record as of June 27, 2025. About Dentsply Sirona Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and

      5/27/25 4:15:00 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care

    $XRAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Mazelsky Jonathan Jay

      4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

      7/2/25 4:25:55 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • EVP & CFO Garth Matthew E was granted 43,023 shares (SEC Form 4)

      4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

      6/3/25 4:48:31 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • SEC Form 3 filed by new insider Garth Matthew E

      3 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

      5/30/25 4:27:32 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care

    $XRAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Dentsply Sirona downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Dentsply Sirona from Overweight to Equal-Weight and set a new price target of $14.00

      4/15/25 9:24:19 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • Dentsply Sirona downgraded by Needham

      Needham downgraded Dentsply Sirona from Buy to Hold

      3/13/25 7:58:34 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • Wells Fargo initiated coverage on Dentsply Sirona with a new price target

      Wells Fargo initiated coverage of Dentsply Sirona with a rating of Equal Weight and set a new price target of $20.00

      2/14/25 7:09:40 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care

    $XRAY
    SEC Filings

    See more
    • SEC Form S-8 filed by DENTSPLY SIRONA Inc.

      S-8 - DENTSPLY SIRONA Inc. (0000818479) (Filer)

      7/1/25 4:21:57 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • DENTSPLY SIRONA Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

      8-K - DENTSPLY SIRONA Inc. (0000818479) (Filer)

      6/12/25 5:20:23 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • SEC Form 8-K filed by DENTSPLY SIRONA Inc.

      8-K - DENTSPLY SIRONA Inc. (0000818479) (Filer)

      6/6/25 8:21:14 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care

    $XRAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Lucier Gregory T bought $249,994 worth of shares (15,142 units at $16.51), increasing direct ownership by 23% to 81,971 units (SEC Form 4)

      4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

      3/3/25 6:33:03 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • Amendment: Director Lucier Gregory T bought $110,129 worth of shares (6,000 units at $18.35), increasing direct ownership by 8% to 66,730 units (SEC Form 4)

      4/A - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

      1/29/25 6:14:01 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • Director Lucier Gregory T bought $110,129 worth of shares (6,000 units at $18.35), increasing direct ownership by 7% to 71,730 units (SEC Form 4)

      4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

      11/18/24 4:16:34 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care

    $XRAY
    Financials

    Live finance-specific insights

    See more
    • Dentsply Sirona Declares Quarterly Cash Dividend

      CHARLOTTE, N.C., May 27, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) announced that its Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, an indicated annual rate of $0.64 per share. The dividend is payable on July 11, 2025, to holders of record as of June 27, 2025. About Dentsply Sirona Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and

      5/27/25 4:15:00 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • Dentsply Sirona Reports First Quarter 2025 Results

      Net sales of $879 million decreased (7.7%), organic sales decreased (4.4%) including a (4.0%) Byte sales impactGAAP gross margin of 53.0%, GAAP net income of $20 million or $0.10 per shareAdjusted gross margin of 56.3%, adjusted EBITDA margin of 19.0%, adjusted EPS of $0.43Maintaining FY25 outlook for organic sales and adjusted EPS; increasing reported sales due to F/X changes CHARLOTTE, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced its financial results for the first quarter of 2025. First quarter net sales of $879 million decreased (7.7%) (organic sales decreased (4.4%)) compared to the first quarter of 2

      5/8/25 6:00:00 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • Dentsply Sirona to Host First Quarter Conference Call on May 8th

      CHARLOTTE, N.C., April 09, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company will be hosting an investor conference call and live webcast on Thursday, May 8, 2025, at 8:30 am ET to review its first quarter financial results. A presentation related to the call will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com. Conference Call / Webcast Information A live webcast will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com. For those planning to participate on the call, please register at https://register-conf

      4/9/25 7:00:00 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care

    $XRAY
    Leadership Updates

    Live Leadership Updates

    See more
    • Dentsply Sirona Appoints Matthew E. Garth as Chief Financial Officer

      CHARLOTTE, N.C., May 29, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Matthew E. Garth has been appointed Executive Vice President and Chief Financial Officer, effective May 30, 2025. Mr. Garth brings nearly 30 years of proven financial management expertise to Dentsply Sirona, with a focus on driving value creation. He most recently served as Chief Financial Officer & Chief Administrative Officer of The Scotts Miracle-Gro Company, a global leader of branded consumer lawn and garden products. Prior to ScottsMiracle-Gro, Mr. Garth held numerous financial leadership roles at large, multinational companies, including Min

      5/29/25 4:30:00 PM ET
      $MTX
      $SMG
      $XRAY
      Major Chemicals
      Industrials
      Agricultural Chemicals
      Medical/Dental Instruments
    • Dentsply Sirona Appoints David Ferguson as Global Business Unit Leader

      CHARLOTTE, N.C., March 17, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (XRAY) today announced that David Ferguson has been appointed Senior Vice President, Global Business Unit Leader, effective March 14, 2025. In this role he will lead the global business unit teams managing the dental product portfolio, serve as a member of the Executive Management Team and report directly to Chief Executive Officer, Simon Campion. David Ferguson joins Dentsply Sirona with 25 years of experience in MedTech and healthcare with a proven track record of delivering results, competing in a global marketplace and leading global product strategy. Mr. Ferguson has se

      3/17/25 8:45:57 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • Dentsply Sirona Appoints Michael Barber and Daniel Scavilla as New Board Members

      CHARLOTTE, N.C., Feb. 06, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Michael J. Barber and Daniel T. Scavilla have been appointed to its Board of Directors (the "Board"), effective February 5, 2025. Mr. Barber brings over 40 years of experience in product management and innovation, including executive leadership roles at GE, where he was responsible for the transformation of the company's digital X-Ray program. Mr. Scavilla, currently CEO of Globus Medical, is a seasoned executive with a deep skillset in commercial deployment and business integration, having successfully led the merger of Globus and NuVasive. Mr. B

      2/6/25 8:30:00 AM ET
      $EXAS
      $GE
      $GMED
      $XRAY
      Medical Specialities
      Health Care
      Consumer Electronics/Appliances
      Technology

    $XRAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by DENTSPLY SIRONA Inc.

      SC 13G/A - DENTSPLY SIRONA Inc. (0000818479) (Subject)

      12/6/24 10:11:29 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by DENTSPLY SIRONA Inc.

      SC 13G - DENTSPLY SIRONA Inc. (0000818479) (Subject)

      11/14/24 1:22:35 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by DENTSPLY SIRONA Inc.

      SC 13G - DENTSPLY SIRONA Inc. (0000818479) (Subject)

      11/12/24 4:23:31 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care